THE AUSTRIAN CENTRE
OF INDUSTRIAL BIOTECHNOLOGY

acib is an international competence centre, developing new, environmentally friendly, economically and technically advanced processes for the biotechnological, pharmaceutical and chemical industry – all of them modelled on nature. acib is bridging the gap between academic research and producing industry. The big advantage for acib partner organisations is the possibility to translate scientific results into concrete processes and product by using scientific know-how, academic infrastructure or industrial networks. Our platform offers tailor-made solutions for our stakeholders from Academia, Industry and Investors.

 LATEST BLOG ARTICLES
  • Getting more oxygen into your system – an innovative way of process intensification
  • Glycobiology meets chemistry to generate tailor-made offspring
  • Project proposal writing and some common pitfalls
  • Plant Microbiota and their natural antibiotic resistances
  • Key for citric acid production discovered
  • Young scientists and the continuous approach of biotechnological production
  • In need of data – paving the way for industry 4.0
  • The 4 letters of Chinese Hamster
  • Enhanced enzymes for safer and faster drug development
  • Targeting cancer
  • Getting more oxygen into your system – an innovative way of process intensification

    More efficiency, more quality, more process safety, less costs, less waste – these are the target specifications of each and every production process in chemical industry. It seems quite ambitious to meet all these requirements, but a new key word has entered the engineering world: process intensification!

    Read more

  • Glycobiology meets chemistry to generate tailor-made offspring

    An interdisciplinary team of scientists is pioneering the development of synthetic glycobiology and trains 15 young researchers in the enabling technologies that underpin the development and exploitation of glycoscience: An exciting topic that promises to bring innovative solutions for the future!

    Read more

  • Project proposal writing and some common pitfalls

    Research funding is a highly competitive process and only a small fraction of applicants get the grant in the end. EU-Horizon 2020, with almost 80 billion Euros the largest research program worldwide, has an average success rate of only 14%. What is the secret of success of those, who have made it? 

    Read more

  • Plant Microbiota and their natural antibiotic resistances

    Antibiotic-resistant bacteria are not only restricted to clinical environments, nor do they always pose an immediate danger for humans. Various environmental niches are occupied by complex microbial communities that also include members that can carry one or different antibiotic resistances. The plant microbiome often harbors highly competitive microorganisms that can shield of pathogens and contribute to the host’s health. In their latest study researchers from acib-partner TU Graz have focused on antibiotic resistances in a common salad plant and found that the indigenous enterobacterial community contributes to the highly interesting profile.

    Read more

  • Key for citric acid production discovered

    The responsible transport gene that allows the production of lemon acid in large quantities was recently discovered. A breakthrough!

    Read more

  • Young scientists and the continuous approach of biotechnological production

    Bioproducts for various applications such as pharmaceuticals, cosmetics, nutrients or industrial enzymes are manufactured with biotechnological methods; microorganisms or immortalized cell lines are the vehicles for production. Due to the long development times such products, especially in the area of pharmaceuticals, are often very expensive. The question is how can we make the production process of bioproducts faster, cheaper and fit for the future.

    Read more

  • In need of data – paving the way for industry 4.0

    What lies behind the data shown on a LCD screen? What do the numbers express and moreover, can we trust them? Is the value displayed correct and can we deduct the right conclusion to set a responsive course of action?

    Read more

  • The 4 letters of Chinese Hamster

    Did you know that nowadays bacteria and mammalian cells, especially hamster cells, produce a wide range of drugs? And who tells them to do so? The answer is the four-letter code of DNA. Biotechnologists spend a lot of time to explore natural DNA sequences of different organisms for production. The Chinese Hamster is a mammalian system and suits well for cell factories because of its similarity to human cells. However, for a long time the knowledge about the hamster DNA sequence had many gaps that needed to be investigated.

    Read more

  • Enhanced enzymes for safer and faster drug development

    Co-author: Martin Walpot

    In the development of drugs and pharmaceutical compounds, expensive tests are necessary, to know, which metabolic by-products and side-effects could emerge and to ensure that drugs are working effectively and in a safe manner. Human-like CYP450 enzymes, which mimic the same activities happening in the human body, are new, excellent biocatalytic tools to screen side effects outside the human body. They also enable the timely production of reasonable amounts of active pharmaceutical ingredients. Used as biocatalysts in industrial applications, new CYP450 enzymes, developed in the EU-project ROBOX, have the potential to speed up drug development, enhance pharmaceutical safety and to innovate chemical markets such as flavour-, fragrance or food industries.

    Read more

  • Targeting cancer

    The complex tumour structure makes the treatment of breast cancer a medical challenge. A promising, novel selenium-based breast cancer nanoparticle therapy, which is topic of the EU-project Neosetac, could change that: It has proved to boost the active agent delivery and assure it’s active only in the target tissue while also bringing the suggestion of reduced side effects. The project findings are expected to increase the efficiency of future chemotherapies and prevent recurrence of the cancer after complete remission.

    Read more

COMPANY PROFILE AND OWNERS

acib is an industrially oriented private limited company with a non-profit orientation. It is publicly owned by:

K2 RESEARCH CENTRE

acib is funded as a K2 research centre in the framework of FFG COMET funding (Competence Centres for Excellent Technologies) by BMVIT, BMWF, and the provinces of Styria, Vienna, Lower Austria and Tyrol. The COMET programme is processed via FFG. 18 scientific partners are involved in the implementation of the acib COMET programme, which is co-funded by 53 industrial partners.

More about COMET



Innovations from Nature 1
Innovations from Nature 4
Innovations from Nature 5
Innovations from Nature 2
Innovations from Nature 3
Innovations from Nature 6